← All trials
NCT06033131
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2024
- Primary completion
- Jul 31, 2027
- Completion date
- Oct 31, 2027
- First posted
- Sep 13, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 294
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GothenburgLead sponsor
- University of GothenburgOverall official - principal investigator
- University of GothenburgSponsor investigator
- The Swedish Research CouncilCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.